Cambridge Healthtech Institute’s Sixth Annual
High-Concentration Protein Formulations:
Analytics, High Viscosity, Aggregation, Devices and Delivery
Part of CHI's Ninth Annual The Bioprocessing Summit

August 23-24, 2017 | Westin Copley Place | Boston, MA


At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high-concentration protein formulations results in several manufacturing, stability, analytical, and delivery challenges. The popular High-Concentration Protein Formulations conference will feature informative, high quality case studies and successful strategies to overcome the problems you are facing with development and delivery of high-concentration protein formulations.

Preliminary Agenda


PROTEIN-PROTEIN INTERACTIONS

Using NMR to Understand Self-Association in Concentrated Protein Solutions

Czeslaw Radziejewski, Ph.D., Senior Principal Research Scientist, Biophysical Chemistry, AbbVie

Probing Complex Protein-Protein Interactions at High Concentrations

Tom Laue, Ph.D., Professor Emeritus, Biochemistry, University of New Hampshire

Predicting High-Concentration Behavior from Low-Concentration Data: Need for Caution

Atul Saluja, Ph.D., Associate Director, Global Pharmaceutical Development – Biologics, Sanofi Genzyme


MEASURING AND MANAGING VISCOSITY

Formulation and Rheological Considerations for High-Concentration Biologics Drug Products

Ashwin Basarkar, Ph.D., Associate Principal Scientist, Merck

A Novel Approach to Directly Measuring Solution Viscosity in a High Throughput Manner

Kimberly Westland, MS, Senior Associate Scientist, Drug Product Technologies, Amgen

Protein-Device Combination and Delivery Strategies for High Dose and High Concentration Delivery

Jifeng Zhang, Ph.D., Senior Director, Global Head of Device-ability, Pharmaceutical Development Biologics, Sanofi Genzyme


PROCESS CONSIDERATIONS FOR HIGH CONCENTRATION FORMULATIONS

Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations

Yuh-Fun Maa, Ph.D., Principal Engineer, Pharmaceutical Processing & Technology Development, Genentech, Inc.- A Member of the Roche Group

Use of First-Principles to Guide Process Development for High Concentration Protein Drug Product

Zhao Yu, Ph.D., Associate Senior Consultant Engineer, Bioproduct Research and Development, Eli Lilly and Company


RAPID EXCIPIENT SCREENING

Rapid Excipient Screening for High Protein Concentration Formulations

Michael S. Marlow, Ph.D., Senior Staff Scientist, Protein Biochemistry, Regeneron Pharmaceuticals, Inc.

Preferential Interactions of Formulation Excipients with High-Concentration IgG1 Monoclonal Antibody Solutions

Chaitanya Sudrik, Postdoctoral Associate, Trout Lab, Chemical Engineering, Massachusetts Institute of Technology




For more details on the conference, please contact:
Nandini Kashyap
Conference Director
Phone: 781-972-5406
Email: nkashyap@healthtech.com

For media partnership opportunities, please contact:
Kaushik Chaudhuri
Director of Product Marketing
Phone: 781-972-5419
Email: kchaudhuri@healthtech.com

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Sherry Johnson
Business Development Manager
Phone: 781-972-1359
Email: sjohnson@cambridgeinnovationinstitute.com

Companies L-Z
Carolyn Benton
Business Development Manager
Phone: 781-972-5412
Email: cbenton@healthtech.com

OutlookYouTubeFacebookLinkedInTwitter #BPSMT

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Event at a Glance
Event at a Glance


Celebrating 25 Years


 

Premier Sponsor

Unchained Labs(1)